Mainly immune phenotype of gastrointestinal stromal tumor and its correlation with risk grading and prognosis
GUO Yingxue1 JIA Jianbin1 NIE Shuangfa2 LI Lei2 WANG Tao2 FEI Jiandong2▲
1.Graduate School, Hebei North University, Hebei Province, Zhangjiakou 075000, China;
2.Department of Gastroenterological Surgery, the First Affiliated Hospital of Hebei North University, Hebei Province, Zhangjiakou 075000, China
Abstract：Objective To analyze gastrointestinal stromal tumors (GIST) immunophenotype and its relationship with risk classification and prognosis. Methods From April 2015 to April 2017, in the First Affiliated Hospital of Hebei North University, 65 GIST patients were selected. The tissue paraffin section were dealed with SABC method, the expression of CD34, CD117, SMA, DOG1, Ki-67, S-100 and Desmin were analyzed, patients were given follow-up. Results The positive rates of CD117, DOG1, S-100 and Desmin were 96.9%, 100.0%, 6.2% and 4.6%, respectively; the positive rates of CD34, SMA and Ki-67 were 89.2%, 29.2% and 29.2% respectively; the positive expression of CD34 was not correlated with mitotic phase, risk grade and tumor size (P > 0.05); the positive expression of SMA was not correlated with mitotic phase, risk phase and tumor size (P > 0.05); Ki-67 expression was positively correlated with mitotic number, risk grade and tumor size (r = 0.715, 0.418, 0.397, P < 0.05); Ki-67 positive recurrence rate was 36.4%, mortality rate was 27.3%, and Ki-67 negative recurrence rate was 6.9%, the mortality rate was 3.4%, and the differences between the two groups were statistically significant (P < 0.05). Conclusion When diagnosing GIST, it can be combined with CD34, CD117 and DOG1, which have better complementarity. Detecting the levels of SMA, S-100 and Desmin protein can improve the accuracy of clinical diagnosis. Combined with Ki-67 factors, the prognosis of patients with GIST can be evaluated effectively.
2018, Vol. 15 
京公网安备 11010502046598号